Dr Udo Haberl is Head of Drug Design at AplaGen GmbH. He obtained a PhD from the University of Bonn, specialising in theoretical organic chemistry and the development of anti-cancer drugs. He is author of molecular modeling software and worked at the University of Notre Dame (US) and at different biotech companies, where he gained 10 years of experience in the design of pharmaceutical drugs. At AplaGen, he focuses on the design and optimisation of peptide sequences, linker structures and new technologies for peptide stabilisation.

Dr Hans-Georg Frank is CSO and co-founder of AplaGen GmbH. He is a physician and obtained his PhD/MD from the Free University of Berlin. He worked scientifically at the Free University of Berlin and the University of Technology in Aachen, Germany, focusing on embryology, developmental biology and oncological topics. Besides working as an academic scientist he also managed clinical studies at Sandoz AG in Nürnberg, Germany. During his academic career he acquired significant grants from The Rockefeller Foundation and the WHO, as well as from the German Research Council, and has published more than 50 articles in peer-reviewed journals. He was also appointed as a Professor at the University of Technology in Aachen. At AplaGen, he focuses on the development of EPO-mimetic peptides.

Dr Marco Emgenbroich is currently Head of the Supportive Organic Chemistry group at AplaGen. His focus is the development of HES-based drug carrier systems. He studied chemistry in Düsseldorf, Germany. He obtained his doctorate degree in 2003 by further specialising in the area of biomimetic polymers. During his PhD studies he joined the DFG-graduate school ‘Molecular Physiology’ and managed the local exhibitions and symposia InCom and LifeCom on the area of bioanalytical chemistry. Before joining AplaGen Marco worked on bioanalytical applications of biomimetic receptors, during his postdoctorate studies in Dortmund, Germany.